Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FX06
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: FX06
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Assistance Publique Hopitaux de Paris
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
Company has announced that the randomized, double-blind, placebo-controlled FX-COVID trial which is conducted by AP-HP (Assistance Publique – Hopitaux de Paris), is set up to confirm the efficacy and safety of FX06 in hospitalized patients receiving mechanical ventilation.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
